Cure My Disease

Don't miss your cure!

 Log in / Sign up

Needle count showdown: does one beat two in lung biopsies?

NCT ID NCT07218042

Knowledge-focused Sponsor: Christopher Kapp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether using one or two needles during a lung biopsy procedure (EBUS bronchoscopy) is better. The goal is to see which approach saves time, costs less, and creates less waste. 126 adults having lymph node sampling took part. The main focus is on time under anesthesia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

126 people

The number who actually took part.

Started

Feb 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Undergoing a bronchoscopy with lymph node sampling Exclusion Criteria: * Unable to get a bronchoscopy procedure for various reasons * Other criteria per protocol uploaded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mediastinal and hilar lymphadenopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mediastinal and hilar lymphadenopathy

Contacts and locations

Locations

  • Duke University

    Durham, North Carolina, 27710, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • University of California, Davis

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.